Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
17 Julho 2023 - 8:00AM
Business Wire
- Can-Fite’s novel approach for the treatment of advanced
liver cancer will be presented at the American Society of Clinical
Oncology (ASCO) Breakthrough Meeting in Japan on August 4th
2023
- Namodenoson is in pivotal Phase 3 study for the treatment
of advanced hepatocellular carcinoma (HCC)
- A patient from the prior Phase 2b study is cancer-free >6
years following initial treatment with Namodenoson
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncology, inflammatory and liver
diseases, today announced its abstract titled “A novel approach for
the treatment of advanced hepatocellular carcinoma (HCC)” is one of
the highest scoring abstracts and has won the prestigious
Breakthrough Abstract Award from Conquer Cancer®, the ASCO
Foundation, and the 2023 ASCO Breakthrough Program Committee.
Can-Fite’s Chief Scientific Officer, Founder, and Executive
Chairman, Dr. Pnina Fishman, will present the poster at the ASCO
Breakthrough Meeting which will take place August 3 – 5, 2023 in
Yokohama, Japan.
Namodenoson has received significant acknowledgment in the
scientific and medical community, as evidenced by the numerous
peer-reviewed publications and conferences in which it has been
published and presented. Currently being evaluated in a pivotal
Phase 3 multinational registration trial for the treatment of HCC
and underlying Child Pugh B7, Namodenoson has also completely
cleared cancer in an HCC patient who was enrolled in Can-Fite’s
Phase 2b HCC trial. The patient continues to be treated through a
compassionate use program in Romania, where she remains cancer-free
more than six years following her first dose of Namodenoson.
“We are honored to receive this prestigious award from Conquer
Cancer and ASCO,” Dr. Fishman stated. “Our Phase 3 registration
trial is designed to treat patients who have tried, yet not
benefitted from the few other FDA-approved HCC treatments on the
market today. We are hopeful that Namodenoson, with its
liver-protective properties, can safely prolong life for advanced
liver cancer patients.”
About Namodenoson
Namodenoson was evaluated in Phase 2 trials for two indications,
as a second line treatment for hepatocellular carcinoma (HCC), and
as a treatment for non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH). It is currently in a Phase 2b
trial for NASH and a pivotal Phase 3 for HCC. Namodenoson is a
small orally bioavailable drug that binds with high affinity and
selectivity to the A3 adenosine receptor (A3AR). A3AR is highly
expressed in diseased cells whereas low expression is found in
normal cells. This differential effect accounts for the excellent
safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an
advanced clinical stage drug development company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's anti-inflammatory drug Piclidenoson reported topline
results in a Phase 3 trial for psoriasis and is expected to
commence a pivotal Phase 3. Can-Fite's cancer and liver drug,
Namodenoson, is being evaluated in a Phase 2b trial for the
treatment of non-alcoholic steatohepatitis (NASH), enrollment is
expected to commence in a Phase 3 trial for hepatocellular
carcinoma (HCC), and the Company is planning a Phase 2a study in
pancreatic cancer. Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug
Administration. Namodenoson has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company's third drug candidate, has shown
efficacy in the treatment of erectile dysfunction. These drugs have
an excellent safety profile with experience in over 1,500 patients
in clinical studies to date. For more information please visit:
www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. All
statements in this communication, other than those relating to
historical facts, are "forward looking statements". Forward-looking
statements can be identified by the use of forward-looking words
such as "believe," "expect," "intend," "plan," "may," "should" or
"anticipate" or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to the COVID-19 pandemic and the Russian invasion of
Ukraine; risks related to not satisfying the continued listing
requirements of NYSE American; and statements as to the impact of
the political and security situation in Israel on our business.
More information on these risks, uncertainties and other factors is
included from time to time in the "Risk Factors" section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
30, 2023 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717115155/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Can Fite BioPharma (AMEX:CANF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024